Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Protagonist Therapeutics Inc shares valued at $257,000 were sold by Waddill William D. on Sep 22 ’25. At $64.25 per share, Waddill William D. sold 4,000 shares. The insider’s holdings dropped to 5,130 shares worth approximately $0.33 million following the completion of this transaction.
Also, WILLIAM WADDILL purchased 4,000 shares, netting a total of over 248,800 in proceeds.
Before that, Waddill William D. had sold 4,000 shares from its account. In a trade valued at $237,000, the Director traded Protagonist Therapeutics Inc shares for $59.25 each. Upon closing the transaction, the insider’s holdings decreased to 4,000 shares, worth approximately $0.59 million.
As published in their initiating research note from Barclays on September 17, 2025, Protagonist Therapeutics Inc [PTGX] has been an Overweight and the price target has been revised to $72. Analysts at Leerink Partners started covering the stock with ‘”an Outperform”‘ outlook in a report released in mid September. As of June 17, 2025, Citigroup has initiated its “Buy” rating for PTGX. Earlier on December 06, 2024, Goldman initiated its rating. Their recommendation was “a Neutral” for PTGX stock.
Analyzing PTGX Stock Performance
On last trading session, Protagonist Therapeutics Inc [NASDAQ: PTGX] plunged -1.90% to $64.7. The stock’s lowest price that day was $64.34, but it reached a high of $66.37 in the same session. During the last five days, there has been a surge of approximately 4.12%. Over the course of the year, Protagonist Therapeutics Inc shares have jumped approximately 40.20%. Shares of the company reached a 52-week high of $66.70 on 09/24/25 and a 52-week low of $33.70 on 02/25/25.
Support And Resistance Levels for Protagonist Therapeutics Inc (PTGX)
According to the 24-hour chart, there is a support level at 63.90, which, if violated, would cause prices to drop to 63.10. In the upper region, resistance lies at 65.94. The next price resistance is at 67.18. RSI (Relative Strength Index) is 65.11 on the 14-day chart, showing neutral technical sentiment.
Is Protagonist Therapeutics Inc subject to short interest?
Stocks of Protagonist Therapeutics Inc saw a sharp rise in short interest on 2025-08-29 jumping by 1.09 million shares to 6.85 million. Data from Yahoo Finance shows that the short interest on 2025-07-31 was 5.76 million shares. A jump of 15.91% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 10.47 of the overall float, the days-to-cover ratio (short ratio) jumped to 10.47.
Which companies own the most shares of Protagonist Therapeutics Inc (PTGX)?
In terms of Protagonist Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 72 in the next 12 months, up nearly 9.17% from the previous closing price of $65.95. Analysts anticipate Protagonist Therapeutics Inc stock to reach 72 by 2025, with the lowest price target being 72. In spite of this, 4 analysts ranked Protagonist Therapeutics Inc stock as Buy at the end of 2025. On December 06, 2024, BMO Capital Markets assigned a price target of “an Outperform” to the stock and initiated coverage with a $62.
